Table 2.
Participants’ characteristics of included studies.
| Author | Year | leptin | R | NOS | |||||
|---|---|---|---|---|---|---|---|---|---|
| Case | Control | ||||||||
| Arumugam R(male) | 1998 | 2.2±1.4 | ng/mL | 3.4±1.2 | ng/mL | 5 | |||
| Arumugam R(female) | 1998 | 7.1±4.1 | ng/mL | 5.4±3.7 | ng/mL | 5 | |||
| Ahme ML (male) | 2004 | 1.07±0.49 | ng/mL | 1.02±0.5 | ng/mL | R1= 0.45 | 5 | ||
| Ahme ML (femle) | 2004 | 2.11±0.86 | ng/mL | 1.34±0.44 | ng/mL | R1= 0.28 | 5 | ||
| Schmitt-Grohe S(mild) | 2006 | 5.22±6.82 | pg/mL | 6.78±9.9 | pg/mL | R2= 0.351 | 8 | ||
| Schmitt-GroheS(moderate) | 2006 | 6.96±11 | pg/mL | 6.78±9.9 | pg/mL | R2= 0.351 | 8 | ||
| Stylianou C(male) | 2006 | 11.27±1.54 | ng/mL | 8.78±5.59 | ng/mL | 7 | |||
| Stylianou C(female) | 2006 | 21.57±7.68 | ng/mL | 14.89±5.71 | ng/mL | 7 | |||
| Boguszewski MC (male) | 2007 | 2.07±0.79 | ng/mL | 3.07±1.28 | ng/mL | R1= 0.6 | 4 | ||
| Boguszewski MC (female) | 2007 | 2.71±0.86 | ng/mL | 5±2.95 | ng/mL | R1= 0.6 | 4 | ||
| Cohen RI (mild) | 2008 | 8.4±1.8 | pg/mL | 8.2±2 | pg/mL | R1=0.56; R2=0.4; R3=0.34 | 7 | ||
| Cohen RI (moderate) | 2008 | 8.1±1.7 | pg/mL | 8.2±2 | pg/mL | 7 | |||
| Cohen RI (severe) | 2008 | 2.4±2 | pg/mL | 8.2±2 | pg/mL | 7 | |||
| Speeckaert MM (male) | 2008 | 2.46±2.24 | ug/L | 6 | |||||
| Speeckaert MM (female) | 2008 | 4.4±3.3 | ug/L | 6 | |||||
| Olveira G(male) | 2012 | 3.9±4.4 | ng/mL | 3.2±1.5 | ng/mL | R1=0.72; R2=0.47; R3=-0.14 | 5 | ||
| Olveira G(female) | 2012 | 12.9±11 | ng/mL | 11.2±4.1 | ng/mL | 5 | |||
| Ziai S(NGT)(male) | 2012 | 2.14±1.9 | pg/mL | 1.57±0.73 | pg/mL | R1=0.82; R2=0.32 | 7 | ||
| Ziai S(AGT)(male) | 2012 | 1.81±1.56 | pg/mL | 1.57±0.73 | pg/mL | 7 | |||
| Ziai S(CFRD)(male) | 2012 | 4.1±3.66 | pg/mL | 1.57±0.73 | pg/mL | 7 | |||
| Ziai S(NGT)(female) | 2012 | 9.24±5.2 | pg/mL | 9.1±6.33 | pg/mL | 7 | |||
| Ziai S(AGT)(female) | 2012 | 9.17±4.13 | pg/mL | 9.1±6.33 | pg/mL | 7 | |||
| Ziai S(CFRD)(female) | 2012 | 6.87±4.57 | pg/mL | 9.1±6.33 | pg/mL | 7 | |||
| Monajemzadeh M(male) | 2013 | 27.16±33.8 | ug/L | 5.15±6.41 | ug/L | 7 | |||
| Monajemzadeh M(female) | 2013 | 13.85±16.8 | ug/L | 8.37±9.08 | ug/L | 7 | |||
| Nowak JK | 2020 | R3=-0.1 | |||||||
| Polito R | 2019 | 9.2±11.2 | ng/mL | 12±6.1 | ng/mL | 8 | |||
| Granados A(NGT) | 2021 | 14.62±14.3 | ug/L | 27.7±21.01 | ug/L | R1=0.31; R2=0.3 | 7 | ||
| Granados A(AGT) | 2021 | 12.05±16.3 | ug/L | 27.7±21.01 | ug/L | 7 | |||
| Granados A(CFRD) | 2021 | 7.9±7.3 | ug/L | 27.7±21.01 | ug/L | 7 | |||
| Galiniak S(male) | 2022 | 12.17±5.65 | ng/mL | 4.97±1.58 | ng/mL | R1=0.5025; R2=0.649; R3=-0.494 | 8 | ||
| Galiniak S(female) | 2022 | 15.78±7.85 | ng/mL | 7.43±2.7 | ng/mL | 8 | |||
NOS, Newcastle-Ottawa Scale; R1, correlation coefficient between leptin concentrations and fat mass; R2, correlation coefficient between leptin concentrations and BMI; R3, correlation coefficient between leptin concentrations and FEV1; NGT, normal glucose tolerance; AGT, abnormal glucose tolerance; CFRD, cystic fibrosis-related diabetes; IGT, impaired glucose tolerance.